The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

Riegger, G. A. J.; Abletshauser, C.; Ludwig, Malte; Schwandt, P.; Widimský, Jiří; Weidinger, Gottfried; Welzel, D

doi:10.1016/s0021-9150(99)00062-3

Cited by 107 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results were consistent with previously observed positive effects of long-term fluvastatin treatment in patients with coronary heart disease or undergoing coronary intervention [38][39][40] . Because the parasympathomimetic activity reflected by the baroreflex activity in turn exerts an antiarrythmogenic effect counteracting the proarrhythmic effect of the sympathetic nervous system, the fluvastatin-ameliorated BRS can contribute to a reduction in cardiac mortality [38][39][40][41] . Undoubtedly, these findings will result in increased interest in the use of fluvastatin to treat diabetic patients with cardiac complications, and the mechanisms behind these effects deserve further study.…”

Section: Discussionsupporting

confidence: 92%

Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats

Xie

Sun

et al. 2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate whether fluvastatin is able to ameliorate the impaired cardiac function or baroreflex sensitivity (BRS) in rats with type 1 diabetes. Methods: Type 1 diabetic rats were induced by intraperitoneal injection of streptozotocin (STZ) and then administered fluvastatin (1.5, 3.0, and 6.0 mg·kg -1 ·d -1 ) for 30 d. Food and drink intake was recorded every day. Fasting blood glucose (FBG) level, blood lipid level, cardiac function and BRS were measured in diabetic rats after fluvastatin treatment for 30 d. Results: The polydipsia, polyphagia and abnormal biochemical indexes of blood were significantly ameliorated by the the 3.0-and 6.0-mg doses of fluvastatin in STZ-induced diabetic rats. FBG was decreased in diabetic rats after fluvastatin treatment for 30 d. The left ventricular systolic pressure (LVSP) and the maximum rate of change of left ventricular pressure in the isovolumic contraction and relaxation period (±dp/dt max ) were elevated, and left ventricular diastolic pressure (LVEDP) was decreased by fluvastatin. The attenuated heart rate responses to arterial blood pressure (ABP) increase induced by phenylephrine (PE) and ABP decrease induced by sodium nitroprusside (SNP) were reversed by the 3.0-mg dose of fluvastatin. Conclusion: Fluvastatin regulates blood lipid levels and decreases the FBG level in diabetic rats. These responses can protect the diabetic heart from complications by improving cardiac function and BRS.

show abstract

Section: Discussionsupporting

confidence: 92%

Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats

Xie

Sun

et al. 2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…Thus, three of the four fluvastatin studies (FLARE, FLORIDA, LIPS) used the maximum dose of 80 mg; the LiSA study increased the starting dose of 40 mg to 80 mg 6 weeks after randomisation if the decrease in LDL-C was less than 30%. 93 Similarly, all but two of the pravastatin studies used the maximum dose of 40 mg; in the remaining two (PLAC II and PMSG), the dose could be increased to 40 mg in participants whose LDL-C levels had not responded to the starting dose of 20 mg. 95,96 Three of the simvastatin studies (Aronow 2003, 101 By contrast, the atorvastatin studies generally used doses well below the maximum dose of 80 mg: ASCOT-LLA and CARDS used a fixed dose of 10 mg, 102,103 and the 4D study a fixed dose of 20 mg. 84 Only the small DALI 86 and Mohler 21 studies used an 80-mg dose: each had two treatment arms, one on a fixed dose of 10 mg and the other on 80 mg.…”

Section: Placebo-controlled Studiesmentioning

confidence: 99%

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

“…Recommendations ) used the maximum dose of 80 mg/day whereas the LiSA study 218 increased the starting dose of 40 mg/day to 80 mg/day 6 weeks after randomisation if the decrease in LDL-c was less than 30%. All but two of the pravastatin studies used the maximum dose of 40mg/day (CAIUS, 219 CARE, 220 PLAC-I, 221 REGRESS 222 ).…”

Section: Chaptermentioning

confidence: 99%

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation

Ara

Pandor²,

Stevens³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in t...

show abstract

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

Cited by 107 publications

References 34 publications

Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats

Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats

A systematic review and economic evaluation of statins for the prevention of coronary events

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation

Contact Info

Product

Resources

About